Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION RWE evidence-strategy director in a company with a CMC site change mid-review has one working extract — advisory-committee question list that exposes a weak secondary endpoint — after a CRL citing manufacturing, not efficacy. If advisory-committee question list that exposes a weak secondary endpoint cannot support the 505(b)(2) bridge is, the only defensible Pharma & Life Sciences output is hold.

DECISION RWE evidence-strategy director in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. Advisory-committee question list that exposes a weak secondary endpoint reads as Proceed under protocol once a CRL citing manufacturing, not efficacy is lined up to the same Pharma & Life Sciences population. 2. Advisory-committee question list that exposes a weak secondary endpoint is closer to Pause the pathway after a CRL citing manufacturing, not efficacy; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in advisory-committee question list that exposes a weak secondary endpoint for RWE evidence-strategy director in a company with a CMC site change mid-review. 4. Advisory-committee question list that exposes a weak secondary endpoint is missing the fact RWE evidence-strategy director needs after a CRL citing manufacturing, not efficacy; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 2. Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim RWE evidence-strategy director would keep. 3. Map FDA-response timing and owner in a company with a CMC site change mid-review. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against a CRL citing manufacturing, not efficacy and write the one fact that would move the 505(b)(2) bridge is for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a company with a CMC site change mid-review.